Cargando…

Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH

Resmetirom (MGL‐3196), a selective thyroid hormone receptor‐β agonist, was evaluated in a 36‐week paired liver biopsy study (NCT02912260) in adults with biopsy‐confirmed nonalcoholic steatohepatitis (NASH). The primary endpoint was relative liver fat reduction as assessed by MRI–proton density fat f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harrison, Stephen A., Bashir, Mustafa, Moussa, Sam E., McCarty, Kevin, Pablo Frias, Juan, Taub, Rebecca, Alkhouri, Naim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034581/ https://www.ncbi.nlm.nih.gov/pubmed/33860116 http://dx.doi.org/10.1002/hep4.1657

Ejemplares similares

Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial
por: Harrison, Stephen A., et al.
Publicado: (2023)

Resmetirom Ameliorates NASH-Model Mice by Suppressing STAT3 and NF-κB Signaling Pathways in an RGS5-Dependent Manner
por: Wang, Xiaojing, et al.
Publicado: (2023)

Looking Into the Crystal Ball: Predicting the Future Challenges of Fibrotic NASH Treatment
por: Alkhouri, Naim, et al.
Publicado: (2019)

Noninvasive Diagnosis of NAFLD and NASH
por: Piazzolla, Valeria Annarita, et al.
Publicado: (2020)

Designing Clinical Trials in Pediatric Nonalcoholic Steatohepatitis: Tips for Patient Selection and Appropriate Endpoints
por: Alkhouri, Naim, et al.
Publicado: (2019)

Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis
por: Javanbakht, Mehdi, et al.
Publicado: (2022)

Solubility determination, dissolution properties and solid transformation of resmetirom (form A) in heptane and seven alcohols
por: Liu, Chang, et al.
Publicado: (2023)

Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis
por: Alkhouri, Naim, et al.
Publicado: (2018)

Correction: Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis
por: Alkhouri, Naim, et al.
Publicado: (2018)

Editorial: Noninvasive Fibrosis Biomarkers in Patients With NASH With Diabetes
por: Fan, Weiguo, et al.
Publicado: (2021)

Prevalence of at-risk NASH and its association with metabolic syndrome in US adults with NAFLD, 2017–2018
por: Payne, Julia Y., et al.
Publicado: (2023)

Noninvasive Testing Using Magnetic Resonance Imaging Techniques as Outcomes in Nonalcoholic Steatohepatitis Clinical Trials: How Full Is the Glass?
por: Noureddin, Nabil, et al.
Publicado: (2020)

Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints
por: Meyer, Elias Laurin, et al.
Publicado: (2023)

Noninvasive measure of treatment response in non‐alcoholic steatohepatitis: Insights from EMMINENCE and meta‐analysis
por: Davison, Beth A, et al.
Publicado: (2021)

AI-based histologic scoring enables automated and reproducible assessment of enrollment criteria and endpoints in NASH clinical trials
por: Iyer, Janani S., et al.
Publicado: (2023)

Resmetirom: An Orally Administered, Smallmolecule, Liver-directed, β-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
por: Karim, Gres, et al.
Publicado: (2023)

The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension
por: Wronski, Samantha L., et al.
Publicado: (2019)

Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH
por: Del Ben, Maria, et al.
Publicado: (2018)

Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness
por: Indira Chandran, Vineesh, et al.
Publicado: (2023)

Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study
por: Amin, Neeta B, et al.
Publicado: (2022)

Cell Autophagy in NASH and NASH-Related Hepatocellular Carcinoma
por: Udoh, Utibe-Abasi S., et al.
Publicado: (2022)

A Noninvasive Score Model for Prediction of NASH in Patients with Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease
por: Liang, Jing, et al.
Publicado: (2017)

Nash vek /
por: Nappelʹbaum, Moisei Solomonovich, 1869-1958
Publicado: (1984)

Nash manifolds
por: Shiota, Masahiro
Publicado: (1987)

Modeling NASH and NASH-Induced Hepatocellular Carcinoma: Faster and Better
por: Hirsova, Petra
Publicado: (2021)

Development of the Rabbit NASH Model Resembling Human NASH and Atherosclerosis
por: Hayashi, Momoko, et al.
Publicado: (2023)

Current therapies and new developments in NASH
por: Dufour, Jean-François, et al.
Publicado: (2022)

Need for better reporting of trials with surrogate endpoints: SPIRIT|CONSORT-SURROGATE extensions
por: Ciani, Oriana, et al.
Publicado: (2022)

From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
por: Gastaldelli, Amalia, et al.
Publicado: (2019)

What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?
por: Alkhouri, Naim, et al.
Publicado: (2021)

Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab‐based model
por: Rabiee, Anahita, et al.
Publicado: (2022)

The essential John Nash
por: Nash, John, et al.
Publicado: (2002)

Molecular Pathogenesis of NASH
por: Caligiuri, Alessandra, et al.
Publicado: (2016)

Natural history of NASH
por: Armandi, Angelo, et al.
Publicado: (2021)

Folate and B12 Levels Correlate with Histological Severity in NASH Patients
por: Mahamid, Mahmud, et al.
Publicado: (2018)

Silent Spontaneous Uterine Rupture at 36 Weeks of Gestation
por: Woo, J. Y., et al.
Publicado: (2015)

Farnesoid X Receptor Agonism, Acetyl‐Coenzyme A Carboxylase Inhibition, and Back Translation of Clinically Observed Endpoints of De Novo Lipogenesis in a Murine NASH Model
por: Gapp, Berangere, et al.
Publicado: (2019)

A Novel Animal Model of Nonalcoholic Steatohepatitis (NASH): Hypoxemia Enhances the Development of NASH
por: Takayama, Fusako, et al.
Publicado: (2009)

The Emerging Role of Extracellular Vesicles and Autophagy Machinery in NASH—Future Horizons in NASH Management
por: Trifylli, Eleni-Myrto, et al.
Publicado: (2022)

Steroid hormonal endpoints in goats carrying single or twin fetuses reared in semi-extensive systems
por: Liotta, Luigi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h5gddrir8tnl315hfpt29m0g06